Tumors with mutations in chromatin regulators are associated with higher mutational burden and improved response to checkpoint immunotherapy

Goran Kungulovski[1,2,*], Marija Gjorgjievska[1], Sanja Mehandziska[1], Djansel Bukovec[1], Milan Risteski[1], Ivan Kungulovski[2], Zan Mitrev[1]

[1]Zan Mitrev Clinic, Skopje, Republic of Macedonia; [2]Fingerprint Diagnostics LLC, Skopje, Republic of Macedonia

**Corresponding author*

Dr. Goran Kungulovski, Fingerprint Diagnostics LLC

Ivan Agovski 7-1, 1000, Skopje, Republic of Macedonia

Phone: +389 70 234280

goran@fingerprintdx.com

goran.kungulovski@zmc.mk

Abstract

In recent years, it has been demonstrated that many of the pervasive genetic defects throughout cancerogenesis occur in genes encoding chromatin regulators (CRs). We analyzed the distribution and characteristics of well-studied CRs across tens of thousands of tumor samples. Our analysis revealed that tumors with mutations in CRs are associated with high tumor mutational burden (TMB). The co-occurrence of mutations in multiple CRs was linked with a further increase in TMB. Given that TMB may predict the clinical response to immune checkpoint inhibitor (ICI) treatment, we investigated the relationship between mutations in CRs and ICI response. We found that patients harboring mutations in CRs exhibited improved responses to ICI treatment, comparable to those with deficiencies in canonical DNA repair pathways. Overall, this study uncovered significant relationships between mutations in chromatin regulators and critical features of cancer, underscoring the need for further functional and clinical studies.

Keywords: cancer epigenetics, cancer genetics, chromatin, immunotherapy, checkpoint inhibitors, tumor mutational burden

INTRODUCTION

Biologically, cancer denotes a multifaceted group of diseases, typically characterized by cell regulation failure, which equips the cells with the potential to divide in an uncontrolled manner, evade the immune system, and over time, invade and spread into neighboring tissues and organs of the body (Hanahan, 2022). Traditionally, cancer has been thought to be driven by the accumulation of genetic defects such as mutations, deletions, amplifications, and translocations in so-called oncogenes and tumor-suppressor genes (Kontomanolis et al., 2020). Consequently, most of the endeavors undertaken in cancer biology

research have historically focused on genetic aberrations in genes with prominent roles in DNA repair, cell proliferation, and cell signaling.

However, in recent years, the widespread application of next-generation sequencing (NGS) technologies for comprehensive cancer profiling has revealed that many of the pervasive genetic defects during carcinogenesis occur in chromatin (epigenetic) regulators (CRs) (Rodrigues-Paredes & Esteller, 2011; Dawson & Kouzarides, 2012; Yu et al., 2024). Such mutations in chromatin writers, readers, erasers, remodelers, and even the histone proteins themselves, can rewire the chromatin landscape of cells, leading to altered epigenetic states and expression programs that contribute to the biological and clinical aspects of tumorigenesis (Baylin & Jones, 2016; Timp & Feinberg, 2013; Feinberg et al., 2016). Hence, a deeper understanding of the distribution, interrelationships, and features of chromatin regulators in cancer can significantly aid our understanding of cancer biology, and treatment.

In this study, we sought to examine the features of a subset of mutated chromatin regulators across tens of thousands of available genetic maps from various cancer types. We uncovered a strong positive relationship between the presence of mutations in CRs and TMB, which in turn was associated with significantly improved survival following treatment with ICI.

RESULTS

Mutations in chromatin regulators are pervasive in cancer and associated with high tumor mutational burden

We commenced by examining the distribution and characteristics of mutations in well-studied chromatin regulators (Timp & Feinberg, 2013; Feinberg et al., 2016) **(Suppl. Data 1)** across tens of thousands of tumor samples. This list is by no means exhaustive in capturing all chromatin regulators frequently mutated in

64 cancer. However, it includes many well-studied CRs that are commonly captured by traditional molecular
65 profiling panels and described in (Timp & Feinberg, 2013; Feinberg et al., 2016). We utilized data from
66 large studies such as the TCGA, MSK-ICI, MSK-MET, PCAWG, and the OrigiMed deposited in the cBioportal
67 platform (TCGA Research Network, 2013; Zehir et al., 2017: Samstein et al., 2019; Consortium, 2020;
68 Nguyen et al., 2022; Wu et al., 2022). Our analysis revealed that mutations in chromatin regulators were
69 pervasive in cancer, especially enriched in particular cancer types such as endometrial, lung,
70 esophagogastric, colorectal, melanoma, and bladder cancer **(Suppl. Figures 1, and 2)**. Given that many of
71 these cancer types are known to be associated with a high mutational load **(Suppl. Figure 2C)** (Chalmers
72 et al., 2017), we sought to ascertain the relationship between the presence of mutations in chromatin
73 regulators and TMB. Tumors with high TMB will theoretically correlate with the probability of a somatic
74 mutation in any part of the genome, including in chromatin regulators (CRs). To demonstrate that the
75 prevalence and distribution of CR mutations are distinct and non-random in high-TMB tumors, we plotted
76 the enrichment of 100 randomly selected non-CR genes alongside canonical tumor suppressors and
77 oncogenes and indeed observed distinct patterns **(Suppl. Figure 2A and B).** Tumors with mutations in the
78 selected CRs had a higher TMB compared to the general cohort or tumors without these CR mutations
79 (**Figure 1A and B, p <0.0001 Kruskal-Wallis test**). Then we wanted to investigate the relationship between
80 tumors harboring single CRs and their effect on TMB levels. We calculated the TMB in tumor samples
81 harboring at least one mutation in a CR gene, in tumors harboring mutations in canonical oncogenes or
82 tumor suppressors, or in tumors harboring mutations in in canonical DNA repair pathways such as the
83 mismatch repair (MMR) machinery or POLE/POLD1 as controls. The presence of mutations in the MMR or
84 POLE/POLD1 machinery has been reported as a proxy marker for high TMB, and ICI-response (Le et al.,
85 2015; Ma et al., 2022). Our results demonstrated significantly higher TMB levels in tumors harboring
86 mutations in certain CRs (e.g *SMARCD1, NSD2, DNMT1, BRD4, TET2, TET1, DNMT3B, EZH1/2*) compared
87 to MMR or POLE/D1 mutated tumors ($p < 0.0001$, Dunnett's multiple comparisons test) (**Figure 1C and D;**

88 **Suppl. Figures 3 and 4; Suppl. Data 2-5**). The types of CRs associated with high TMB were reproducible
89 across datasets, indicating the non-random distribution of CRs in tumor samples (**Suppl. Figure 5**).

90 The co-occurrence of mutations in chromatin regulators leads to additional
91 increases in TMB

92 Next, we were curious to ascertain if the co-occurrence of mutations in two or more CRs would have an
93 enhancing effect on the levels of TMB as displayed in the red box in (**Figure 2A**). Indeed, by analyzing the
94 MSK-ICI data, we observed that the simultaneous presence of mutations in multiple CRs had a strong linear
95 relationship with TMB levels (Pearson's $r = 0.87$, $R^2 = 0.76$, $p < 0.0001$) (**Figure 2B**). A positive relationship
96 was also observed when mutations were simultaneously present in multiple genes of the MMR machinery
97 and/or POLE/D1 (Pearson's $r = 0.68$), albeit with lower predictability ($R^2 = 0.46$) (**Suppl. Figure 6A**). This was
98 not the case when TMB levels were assessed in association with co-occurring mutations in canonical
99 oncogenes and tumor suppressors (Pearson's $r = 0.43$, $R^2 = 0.18$) (**Suppl. Figure 6B**). Then we selected the
100 top 10 high-TMB CRs from the MSK-ICI and TCGA datasets (**Figure 2A; Suppl. Figure 1**). By calculating the
101 log2 odds ratio against all other CRs, and controls (MMR and POLE/D1) we discovered statistically
102 significant associations of co-occurrence (**Suppl. Data 6 and 7**), which again led to significant increases of
103 TMB ($p < 0.0001$, Dunnett's multiple comparisons test) (**Figure 2C; Suppl. Figures 7, and 8**). A similar
104 cumulative effect leading to increased levels of TMB was observed when mutations in CRs and MMR or
105 POLE/D1 were present at the same time, with CRs having a stronger effect on the TMB levels in MMR and
106 POLE/D1 samples than vice versa (**Suppl. Figure 9A and B**). Similar observations were made when we
107 selected the top 10 high TMB-associated CR and non-CR genes (out of 100 randomly selected non-CR
108 genes), and showed that the top 10 CRs had a stronger effect on the TMB levels in top 10 non-CR samples
109 than vice versa, again showcasing the effect of CRs on TMB **(Suppl. Figure 9C and D)**. All in all, these
110 observations were consistently corroborated across multiple independent datasets, demonstrating that

111 single or co-occurring mutations in chromatin regulators or other high TMB-associated genes are strongly
112 linked to higher TMB.

113 Mutations in chromatin regulators lead to improved response to checkpoint
114 immunotherapy

115 Next, we set out to examine the association between the presence of mutations in CRs, and overall survival
116 after treatment with ICI. We used the MSK-ICI cohort (Samstein et al., 2019), which included 1661 patients
117 whose tumors were profiled with the MSK-IMPACT assay, and who had received at least one dose of ICI as
118 monotherapy or combination. As indicated in the original study, the overall survival was measured from
119 the date of the first ICI treatment to the time of death or most recent follow-up (median 19 months, range
120 0-80). We corroborated the initial observation showing that higher TMB levels are associated with better
121 outcomes (**Suppl. Figure 10**)**.** Further on, we defined subgroups based on the presence of mutations in
122 selected CRs (e.g. top 10, high TMB CRs), MMR, or POLE/D1 as positive controls (likely responders) versus
123 the average of the entire cohort. The analysis showed that the group of high TMB CRs was associated with
124 improved survival compared to the entire cohort, and on par with MMR or POLE/D1 deficient tumors
125 (**Figure 3A**). Univariate Cox proportional-hazards regression showed the presence of CR mutations was
126 significantly associated with better survival (all CRs, HR = 0.8520, p = 0.0075; TOP5 CRs, HR = 0.5758, p <
127 0.0007; TOP10 CRs, HR = 0.6845, p < 0.0001), on par with MMR (HR = 0.6162, p = 0.0025), and POLE/D1
128 (HR = 0.6576, p = 0.0074) deficient patients. Moreover, we analyzed the distribution of mutated CRs in
129 living and deceased patients by calculating the ratio, of a CR in living and deceased patients for each CR
130 individually. We observed a significant enrichment of high TMB CRs in living vs deceased patients (HR
131 ranging from 0.32 up to 1.38) (**Figure 3B; Suppl. Data 8**). To demonstrate that the beneficial effect is
132 attributed to the ICI treatment, and not to a general benefit obtained from the mere presence of mutations
133 in CRs, we compared the ratio of CRs in living and deceased patients taken from the MSK-ICI study (ICI-

134 treated), to those from the MSK-MET, and TCGA studies (variously treated). We observed a low-to-no
135 correlation between these datasets (MSK-ICI vs MSK-MET, $r > 0.36$ and MSK-ICI vs TCGA, $r < -0.06$) (**Suppl.**
136 **Figure 11A and B**). In addition, there was a negligible or no association between high TMB CRs and
137 improved survival in the MSK-MET and TCGA studies (TOP10 MSK-MET genes HR=0.90, $p < 0.0003$; TOP10
138 MSK-ICI genes HR=0.95, p=0.05; TOP10 TCGA genes HR=1.01, $p = 0.78$; TOP10 MSK-ICI genes, HR=0.99,
139 p=0.87) (**Suppl. Figure 11C and D**). In summary, the above data show a strong association between the
140 presence of mutations in selected CRs and improved survival due to ICI treatment.

141 DISCUSSION

142 The findings of our study highlight the critical role of chromatin regulators in cancer biology and their
143 potential as biomarkers for predicting tumor mutational burden and response to immune checkpoint
144 inhibitors. This is in agreement with previous studies associating CRs such as *SMARCA4* and *ARID1A* with
145 TMB and improve ICI response (Ravi et al., 2023; Wang et al., 2023) Our analysis, which encompassed tens
146 of thousands of tumor samples from publicly available biorepositories, demonstrated that mutations in
147 CRs are widespread across various cancer types and are significantly associated with elevated TMB,
148 particularly pronounced in cancers known to have a high mutational load. This underlines the importance
149 of epigenetic dysregulation in cancer formation, progression, and treatment, and at the same time alludes
150 that some cancers might be more dependent on genetically induced epigenetic changes than others.

151 Our observation that tumors harboring CR mutations exhibit higher TMB compared to those without such
152 mutations underscores the importance of CRs in influencing the mutational landscape of cancers. Our
153 results indicate that single mutations in CRs are sufficient to increase TMB levels, and this effect is
154 amplified when multiple CR mutations co-occur together or with another high TMB associated gene. The
155 strong linear relationship between the number of CR mutations and TMB, suggests that the detection of

156 mutations CR and repair machinery mutations through the application of small, and cost-effective gene
157 panels could be a reliable predictor of TMB. Although CRs significantly impact TMB, they likely do not fully
158 account for the presence of high TMB in tumors. Further studies are needed to explore the complex
159 relationship between high TMB and other individual genes or gene groups, whether CRs or non-CRs in
160 multivariate analyses.

161 We also explored the clinical implications of CR mutations in the context of ICI treatment. Despite the
162 heterogeneity, heavy pretreatment, and variable ICI-timing of the MSK-ICI cohort our analysis revealed
163 that patients with tumors harboring CR mutations had improved survival outcomes following ICI therapy.
164 These outcomes were comparable to those with MMR- or POLE/D1 deficient tumors, which are
165 traditionally associated with high TMB and favorable ICI responses. The association of CR mutations with
166 increased levels of TMB, and improved ICI outcomes in such a heterogeneous cohort highlights the
167 robustness of our observations, suggesting that mutations in CRs could serve as clinically meaningful
168 predictive biomarkers to inform clinical decisions regarding ICI treatment, and should be included in tumor
169 profiling panels.

170 The mechanism by which mutations in CRs systematically dysregulate the epigenome, leading to elevated
171 TMB and improved response can be delineated in two ways. Firstly, the dysregulated epigenome might
172 cause deficiencies in genome maintenance and repair, resulting in a hypermutable state that might yield
173 a higher number of tumor neoantigens, and thus facilitate an improved immune response. Secondly, the
174 dysregulated epigenome might enhance the expressivity of already established neoantigens, facilitating a
175 more robust immune response and better outcomes. Investigating the mechanistic pathways through
176 which CR mutations influence TMB and enhance ICI efficacy could provide deeper insights into cancer
177 immunotherapy and lead to more personalized treatment approaches. Additionally, expanding this
178 research to include other cohorts and cancer types will be crucial to confirm the generalizability of our

179 results. These findings collectively emphasize the need for further functional and clinical studies to validate
180 the role of CR mutations as biomarkers for TMB and ICI response.

181 In conclusion, our study elucidates the significant relationships between chromatin regulator mutations,
182 tumor mutational burden, and clinical outcomes following ICI treatment. These insights not only advance
183 our understanding of the epigenetic underpinnings of cancer but also pave the way for developing novel
184 biomarkers and therapeutic strategies to improve patient outcomes in cancer immunotherapy.

185 MATERIALS AND METHODS

186 Datasets used in the study

187 All genomic datasets used in this study were downloaded from the cBioportal platform,
188 http://www.cbioportal.org/, and were statistically analyzed, and visualized using various tools including
189 Microsoft Excel, Google Sheets, StatsDirect, Prism, and integrated tools within the cBioportal platform,
190 such as Oncoprint (Cerami et al., 2012; Gao et al., 2013). Datasets in the study include the Tumor Cancer
191 Genome Atlas (TCGA; 10967 samples), this is a landmark cancer genomics program, molecularly
192 characterized over 20,000 primary cancer and matched normal samples spanning 33 cancer types;
193 Memorial Sloan Kettering-Metastatis Events and Tropisms (MSK-MET; 25775 samples), this is a pan-
194 cancer cohort of tumor genomic and clinical outcome data and it identifies associations between tumor
195 genomic alterations and patterns of metastatic dissemination across 50 tumor types; Memorial Sloan-
196 Kettering Immune Checkpoint Inhibitors (MSK-ICI; 1661 samples), this is a genomic and survival data from
197 tumor-normal pairs from patients with various cancer types sequenced with the MSK-IMPACT assay; The
198 ICGC/TCGA Pan-Cancer Analysis of Whole Genomes consortium (PCAWG; 2922 samples), this study
199 encompasses whole-cancer genomes and their matched normal tissues across 38 tumor types; and the
200 China PanCancer consortium (OrigiMed; 10194 samples), encompasses the landscape of genomic

201 alterations in solid tumors from the Chinese population. All the datasets are deposited in the cBioportal
202 platform (TCGA Research Network, 2013; Zehir et al., 2017: Samstein et al., 2019; Consortium, 2020;
203 Nguyen et al., 2022; Wu et al., 2022). The number of samples per subgroup used in this study can be
204 found in **Suppl. Data 9**. The TCGA dataset was sequenced using whole exome sequencing (WES), whilst
205 the PCAWG dataset was sequenced with whole genome sequencing (WGS). The remaining datasets were
206 obtained via targeted panel sequencing. Specifically, the MSK-ICI and the MSK-MET datasets were
207 generated using the FDA-approved MSK-IMPACT assay, which targets 341-468 cancer-related genes
208 (Cheng, et al., 2015). The OrigiMed sequences were acquired using the CSYS assay, targeting 450 cancer-
209 related genes (Cao, et al., 2019).

210 Statistical analysis

211 Statistical analyses were conducted using the Kruskal-Wallis non-parametric exact test for multiple-group
212 comparisons to account for distribution differences among the samples. Dunnett's multiple comparisons
213 test was used to compare each group with a single control. Multiple pairwise comparisons were calculated
214 post-hoc with the Dunn's test. Survival data were analyzed and interpreted using the Cox proportional
215 hazards model and Kaplan-Meier curves, with comparisons made using the log-rank test. Simple linear
216 regression was employed to model the relationship between TMB and co-occurring mutations. To
217 evaluate the strength of linear relationships between continuous variables, the Pearson correlation
218 coefficient was calculated.

219 Declarations

220 Ethics approval and consent to participate

221 Not applicable. All data are taken from publicly available datasets and cancer projects.

Consent for publication

Not applicable. All data are taken from publicly available datasets and already reported in the literature.

Availability of data and material

All data are publicly available at the cBioportal repository, http://www.cbioportal.org.

Funding

Privately funded by Fingerprint Diagnostics LLC and Zan Mitrev Clinic.

Author contributions

GK conceived and designed this study. GK, MG, SM, and DjB collected, sorted, curated, and analyzed the data. MR, IK and ZM provided valuable scientific insights. GK wrote the manuscript. All authors contributed to the improvement of the manuscript and read the final version of the manuscript.

Acknowledgments

We would like to acknowledge Aleksandar Trifunovski, Aleksandra Horvat, and Bobi Sofronijoski for their assistance in data sorting and integration. We are grateful to Maria Kitanoska and Tamara Cvetkovska for their help in data collection and curation.

REFERENCES

1. Hanahan, D. Hallmarks of Cancer: New Dimensions. Cancer Discovery 12, 31-46 (2022).

2. Kontomanolis, E.N. et al. Role of Oncogenes and Tumor-suppressor Genes in Carcinogenesis: A Review. Anticancer Res 40, 6009-6015 (2020).

3. Rodríguez-Paredes, M. & Esteller, M. Cancer epigenetics reaches mainstream oncology. Nat Med 17, 330-9 (2011).

4. Dawson, M.A. & Kouzarides, T. Cancer epigenetics: from mechanism to therapy. Cell 150, 12-27 (2012).

5. Yu, X. et al. Cancer epigenetics: from laboratory studies and clinical trials to precision medicine. Cell Death Discov 10, 28 (2024).

6. Baylin, S.B. & Jones, P.A. Epigenetic Determinants of Cancer. Cold Spring Harb Perspect Biol 8(2016).

7. Timp, W. & Feinberg, A.P. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer 13, 497-510 (2013).

8. Feinberg, A.P., Koldobskiy, M.A. & Göndör, A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Genet 17, 284-99 (2016).

9. Genomics, N.C.I.C.F.C. The Cancer Genome Atlas Program (TCGA). (NIH, 2006).

10. Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 23, 703-713 (2017).

11. Samstein, R.M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 51, 202-206 (2019).

12. Pan-cancer analysis of whole genomes. Nature 578, 82-93 (2020).

13. Nguyen, B. et al. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell 185, 563-575.e11 (2022).

14. Wu, L. et al. Landscape of somatic alterations in large-scale solid tumors from an Asian population. Nat Commun 13, 4264 (2022).

15. Chalmers, Z.R. et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 9, 34 (2017).

16. Le, D.T. et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 372, 2509-20 (2015).

17. Ma, X., Dong, L., Liu, X., Ou, K. & Yang, L. POLE/POLD1 mutation and tumor immunotherapy. J Exp Clin Cancer Res 41, 216 (2022).

18. Ravi, A. et al. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nat Genet 55, 807-819 (2023).

273 19. Wang, D. et al. Relationship among DDR gene mutations, TMB and PD-L1 in solid tumour genomes
274 identified using clinically actionable biomarker assays. NPJ Precis Oncol 7, 103 (2023).

275 20. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional
276 cancer genomics data. Cancer Discov 2, 401-4 (2012).

277 21. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the
278 cBioPortal. Sci Signal 6, pl1 (2013).

279 22. Cheng, D.T. et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer
280 Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid
281 Tumor Molecular Oncology. J Mol Diagn 17, 251-64 (2015).

282 23. Cao, J. et al. An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and
283 Immunotherapies. Oncologist 24, e1294-e1302 (2019)


A)
TCGA dataset
TMB
CRs
Cohort
Cohort w/o CRs
B)
MSK – ICI dataset
TMB
CRs
Cohort
Cohort w/o CRs
C)
TMB
D)
TMB

284

285

286 **Figure 1**. Distribution of tumor mutational burden (TMB) in relevant groups of samples. A) Samples with
287 mutations in chromatin regulators (CRs) n=5321, the cohort n=10443, and the cohort with CR genes removed
288 n = 5122, taken from the TCGA dataset, B) Samples with mutations in chromatin regulators (CRs) n=935, the
289 cohort n=1661, and the cohort with CR genes removed n=726, taken from the MSK-ICI dataset. The bars show
290 the mean of the group, while the error bars represent the standard error of the mean (SEM). Statistical
291 significance was calculated with the Kruskal-Wallis test. C) Samples with mutations in single chromatin
292 regulators (CRs), samples with mutations in canonical oncogenes and tumor-suppressor genes, and samples
293 with mutations in MMR-genes and *POLE*, and *POLD1*, taken from the TCGA dataset. The median of the analyzed
294 samples is 312. D) Samples with mutations in single chromatin regulators (CRs), samples with mutations in
295 canonical oncogenes and tumor-suppressor genes, and samples with mutations in MMR-genes and *POLE* and
296 *POLD1*, taken from the MSK-ICI dataset. The median of the analyzed samples is 102. The graph represents the
297 median with 95% confidence intervals (CI). The red boxes indicate the positive and negative controls.
298 Supplementary Figures 1-5 are related to this figure. The statistical significance between samples can be found
299 in Supplementary Data 2-5 calculated with the Dunn's multiple comparisons test. The number of samples per
300 subgroup used in this study can be found in Suppl. Data 9


A)
Overall Survival Status
TMB (nonsynonymous)
SMARCD1 1.1%
DNMT1 3%
BRD4 2.9%
ARID1B 5%
TET2 5%
ARID2 6%
TET1 3%
DNMT3B 2.2%
EP300 5%
EZH2 2.4%
DAXX 1.7%
KMT2A 7%
NSD1 4%
KDM5A 2.8%
KMT2C 10%
CREBBP 7%
SMARCA4 8%
KMT2D 14%
IDH1 2.8%
DNMT3A 2.6%
ARID1A 12%
KDM5C 4%
ATRX 7%
SETD2 8%
KDM6A 5%
SMARCB1 1.2%
PBRM1 8%
Genetic Alteration
Inframe Mutation (putative driver)
Inframe Mutation (unknown significance)
Missense Mutation (putative driver)
Missense Mutation (unknown significance)
Splice Mutation (putative driver)
Splice Mutation (unknown significance)
Truncating Mutation (putative driver)
Truncating Mutation (unknown significance)
Structural Variant (putative driver)
Structural Variant (unknown significance)
No alterations
Overall Survival Status
0:LIVING
1:DECEASED
TMB (nonsynonymous)
0
207.49
B)
$R^2 = 0.76$
$p < 0.0001$
No. mutations in CRs
TMB
C)
TMB
DNMT1
DNMT1 - KMT2D
DNMT1 - KMT2C
DNMT1 - SETD1A
DNMT1 - EP300
DNMT1 - HDAC9
DNMT1 - CREBBP
DNMT1 - KMT2A
DNMT1 - PRDM9
DNMT1 - ING1
DNMT1 - NSD2
DNMT1 - EZH1/2
DNMT1 - NSD1
DNMT1 - TET3
DNMT1 - TET1
DNMT1 - SETD2
DNMT1 - KDM6A
DNMT1 - SETD1B
DNMT1 - HDAC4
DNMT1 - KDM5C
DNMT1 - HDAC2
DNMT1 - BRD4
DNMT1 - PHF23
DNMT1 - KDM2B
DNMT1 - TET2
DNMT1 - MBD1
DNMT1 - PHF6
DNMT1 - BRD8
DNMT1 - MBD4

301

302 **Figure 2.** Co-occurrence of chromatin regulators leads to increased TMB. A) Oncoprint analysis of the
303 distribution and prevalence of genomic alterations in CRs corresponding to overall survival status, and TMB.
304 The red box visually displays the association of co-occurring mutations in CRs with increased levels of TMB, B)
305 Simple linear regression model showing that TMB can be predicted based on the number of co-occurring
306 mutations in multiple CRs. The datasets are taken from the MSK-ICI study. C) Statistically significant associations
307 of co-occurrence between DNMT1 with other CRs lead to a further increase in TMB. The graph represents the
308 median with 95% confidence intervals (CI). The datasets are taken from the TCGA study. Supplementary Figures
309 1, 6-9 are related to this figure. The statistical significance between samples can be found in Supplementary
310 Data 6 and 7. The number of samples per subgroup used in this study can be found in Suppl. Data 9.

A)



No. at risk (number censored)									
MMR	100 (121)	75 (67)	69 (40)	57 (20)	57 (9)	/	/	/	45 (1)
POLE/D1	100 (116)	77 (74)	64 (36)	52 (17)	48 (7)	/	/	/	/
TOP10 CRs	100 (404)	72 (237)	60 (124)	55 (61)	53 (25)	/	/	/	44 (1)
Cohort	100 (1630)	64 (889)	49 (429)	40 (195)	35 (84)	28 (33)	22 (15)	20 (6)	20 (2)

B)



311

312 **Figure 3**. ICI-survival analysis in selected groups of patients taken from the MSK-ICI dataset. A) Kaplan-Meier
313 survival analysis between patients with mutations in the TOP 10 high TMB CRs, mutations in the MMR genes,
314 and mutations in the *POLE* or *POLD1* genes compared with the cohort. The Cox proportional hazards model
315 was used to calculate hazard ratios. B) The distribution of mutated CRs, mutated oncogenes or tumor-
316 suppressors, mutated MMR-genes or *POLE,* and *POLD1* in living and deceased patients who underwent ICI
317 treatment. The datasets are taken from the MSK-ICI study. Supplementary Figures 10 and 11 are related to this
318 figure. The Cox hazard ratios for each CR can be found in Suppl. Data 8. The number of samples per subgroup
319 used in this study can be found in Suppl. Data 9.

320